Quantcast
Last updated on April 19, 2014 at 17:21 EDT

Latest atrial flutter Stories

2013-12-23 08:26:14

DUBLIN, December 23, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/jnp98l/atrial) have announced the addition of the "Global Atrial Fibrillation Market Report 2013 - 2019" [http://www.researchandmarkets.com/research/jnp98l/atrial ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Atrial fibrillation is a type of cardiac arrhythmia identified by an abnormal cardiac rhythm caused by a...

2013-12-17 12:26:46

DUBLIN, Dec. 17, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/lvjnqv/cardiac_rhythm) has announced the addition of the "Cardiac Rhythm Management Devices World Markets" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 In the last five decades, electronic cardiac medicine has witnessed dramatic technological developments. The cardiac rhythm management products mainly marketed by a handful of global players are used to treat...

2013-11-18 08:29:00

ChanRx Presents Study Results at 2013 American Heart Association Scientific Sessions DALLAS, Nov. 18, 2013 /PRNewswire/ -- ChanRx, a pharmaceutical company developing medicines for cardiovascular diseases, today announced positive safety and statistically significant efficacy data from a Phase IIb study of vanoxerine (GBR-12909), a drug in development for the treatment of atrial fibrillation. The data were presented yesterday at the American Heart Association 2013 Scientific...

2013-11-12 08:35:17

CLEVELAND, Nov. 12, 2013 /PRNewswire/ -- ChanRx, a firm developing medicines for cardiovascular diseases, today announced that it will be presenting the results of its Phase IIb study of vanoxerine (GBR-12909), a drug under study for the treatment of atrial fibrillation, at the American Heart Association 2013 Scientific Sessions conference. The study, titled "COR-ART: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose Modification Study to Evaluate Single Oral Doses of...

2013-11-01 23:04:34

Transparency Market Research adds new "Atrial Fibrillation Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" market research report to its report store. Browse the report with request TOC; visit http://www.transparencymarketresearch.com/atrial-fibrillation-market.html. Albany, New York, USA (PRWEB) November 01, 2013 According to a new market report published by Transparency Market Research "Atrial Fibrillation Market (Pharmacological...

2013-10-28 20:24:51

BERLIN, October 29, 2013 /PRNewswire/ -- Atrial fibrillation is an under-diagnosed, undertreated abnormal heart rhythm that increases stroke risk five-fold compared to the general population World Stroke Day 2013 By World Stroke Day 2013 (October 29) more than 500,000 people have shown their support for the Sign Against Stroke in Atrial Fibrillation campaign, calling for urgent coordinated action to avoid the thousands of preventable strokes that...

2013-05-13 13:14:52

New technology maps the electronic signals of the heart 3 dimensionally Researchers at the Intermountain Heart Institute at Intermountain Medical Center have developed a new 3-D technology that for the first time allows cardiologists the ability to see the precise source of atrial fibrillation in the heart — a breakthrough for a condition that affects nearly three million Americans. This new technology that maps the electronic signals of the heart three dimensionally significantly...

2013-05-10 08:25:28

Company Offers Mapping System with IntellaMap Orion(TM) Mapping Catheter in Effort to Significantly Enhance Physician Treatment Options NATICK, Mass., May 10, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the Rhythmia(TM) Mapping System, a next-generation 3D mapping and navigation solution for use in cardiac catheter ablations and other electrophysiology (EP) procedures to treat a variety of conditions in which the heart beats...

2013-05-06 08:30:18

NATICK, Mass., May 6, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) completed a first-in-human clinical trial utilizing the IntellaTip MiFi(TM) XP Ablation Catheter for the treatment of type 1 atrial flutter, an arrhythmia originating in the right atrium of the heart that affects nearly one million people in the United States. This single center feasibility trial enrolled 10 patients and was led by Prash Sanders, MBBS, PhD, FHRS, director of the Centre for Heart Rhythm...

2013-04-24 08:29:20

ANN ARBOR, Mich., April 24, 2013 /PRNewswire/ -- Leading cardiovascular scientists today announced the launch of avert-AF, a new initiative aimed at developing drug treatments for the prevention of the more advanced forms of atrial fibrillation. Atrial fibrillation (AF or A-fib) is the most common cardiac arrhythmia (irregular heart beat). Although it may not cause any symptoms, it is often associated with palpitations, fainting, chest pain, or congestive heart failure. Atrial...